恩替卡韦与复方甘草酸苷联用对慢性乙型病毒性肝炎患者肝纤维化的影响和安全性  

Effect and Safety of Entecavir Combined with Compound Glycyrrhizin on Liver Fibrosis in Patients with Chronic Hepatitis B

作　　者：陈美玲 吴国文 李秋文 CHEN Meiling;WU Guowen;LI Qiuwen(Department of Infectious Diseases,Fuzhou Changle District People's Hospital,Fuzhou,Fujian,350200,China)

机构地区：[1]福州市长乐区人民医院感染科,福建福州350200

出　　处：《中外医疗》2025年第8期61-64,共4页China & Foreign Medical Treatment

摘　　要：目的研讨恩替卡韦与复方甘草酸苷联用对慢性乙型病毒性肝炎(chronic hepatitis B,CHB)患者肝纤维化的影响。方法随机选取2021年2月—2024年2月福州市长乐区人民医院收治的60例CHB患者为研究对象,根据不同治疗方法分为两组,各30例。对照组单用恩替卡韦,观察组采用恩替卡韦与复方甘草酸苷联用,比较两组的病毒学指标、肝功能、肝纤维化状况以及用药安全性。结果观察组乙肝病毒-DNA转阴率为80.00%(24/30)、乙型肝炎e抗原转阴率为53.33%(16/30),高于对照组的53.33%(16/30)和26.67%(8/30),差异均有统计学意义(χ^(2)=4.800,4.444;P均<0.05)。治疗后,观察组肝功能指标水平和肝纤维化指标水平均低于对照组,差异均有统计学意义(P均<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论恩替卡韦与复方甘草酸苷联用可提升CHB患者的病毒指标转阴率,改善其肝功能及肝纤维化,且不影响用药安全。Objective To investigate the effect of entecavir combined with compound glycyrrhizin on liver fibrosis in patients with chronic hepatitis B(CHB).Methods From February 2021 to February 2024,60 patients with CHB admitted to Fuzhou Changle District People's Hospital were randomly selected as the research objects.According to different treatment methods,they were divided into two groups,30 cases in each group.The control group was treated with entecavir alone,and the observation group was treated with entecavir combined with compound glycyrrhizin.The virological indexes,liver function,liver fibrosis and drug safety were compared between the two groups.Results The negative conversion rates of hepatitis B virus-DNA and hepatitis Be antigen in the observation group were 80.00%(24/30)and 53.33%(16/30),which were higher than 53.33%(16/30)and 26.67%(8/30)in the control group,and the differences were statistically significant(χ^(2)=4.800,4.444;both P<0.05).After treatment,the levels of liver function indexes and liver fibrosis indexes in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of entecavir and compound glycyrrhizin can increase the negative conversion rate of viral indicators in CHB patients,improve their liver function and liver fibrosis,and do not affect the safety of medication.

关 键 词：慢性乙型病毒性肝炎 恩替卡韦 复方甘草酸苷 肝纤维化 安全性 

分 类 号：R512.62[医药卫生—内科学]